Should I buy or sell AbbVie stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares. View ABBV analyst ratings or view top-rated stocks .

What is AbbVie's stock price target for 2024?

15 brokerages have issued 12-month price targets for AbbVie's shares. Their ABBV share price targets range from $150.00 to $196.00. On average, they anticipate the company's share price to reach $175.36 in the next year. This suggests a possible upside of 0.7% from the stock's current price. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts .

How have ABBV shares performed in 2024?

AbbVie's stock was trading at $154.97 at the start of the year. Since then, ABBV stock has increased by 12.3% and is now trading at $174.08. View the best growth stocks for 2024 here .

Are investors shorting AbbVie?

AbbVie saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 13,560,000 shares, an increase of 12.3% from the December 31st total of 12,080,000 shares. Based on an average trading volume of 5,580,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.8% of the shares of the company are short sold. View AbbVie's Short Interest .

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our ABBV earnings forecast .

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its earnings results on Friday, February, 2nd. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.76 by $0.03. The business had revenue of $14.30 billion for the quarter, compared to analysts' expectations of $14.02 billion. AbbVie had a trailing twelve-month return on equity of 154.73% and a net margin of 8.95%. The business's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.60 earnings per share. Read the conference call transcript .

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 27th. Investors of record on Tuesday, January 16th will be given a dividend of $1.55 per share on Thursday, February 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Friday, January 12th. This is a positive change from the stock's previous quarterly dividend of $1.48. Read our dividend analysis for ABBV .

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.56%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 50.99% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for ABBV .

What ETFs hold AbbVie's stock?

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL) , First Trust Nasdaq Pharmaceuticals ETF (FTXH) , Horizon Kinetics Medical ETF (MEDX) , iShares Core High Dividend ETF (HDV) , Invesco Pharmaceuticals ETF (PJP) , Simplify Health Care ETF (PINK) , Health Care Select Sector SPDR Fund (XLV) and VanEck Pharmaceutical ETF (PPH) .

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its first quarter 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of 2.300-2.340 for the period, compared to the consensus estimate of 2.310. The company issued revenue guidance of $11.9 billion-$11.9 billion, compared to the consensus revenue estimate of $11.4 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com . Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC) , Constellation Software (CSU) , AutoCanada (ACQ) , Alimentation Couche-Tard (ATD.B) , Vermilion Energy (VET) , AT&T (T) , Bristol-Myers Squibb (BMY) , Rogers Communications (RCI) and Open Text (OTEX) .

Who are AbbVie's major shareholders?

AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (1.36%), Norges Bank (1.16%), Massachusetts Financial Services Co. MA (0.47%), Dimensional Fund Advisors LP (0.45%), Franklin Resources Inc. (0.42%) and California Public Employees Retirement System (0.34%). Insiders that own company stock include Azita Saleki-Gerhardt , Brian L Durkin , Carrie C Strom, Carrie C Strom , Elaine K Sorg , Henry O Gosebruch , Jeffrey Ryan Stewart , Laura J Schumacher , Michael Severino , Nicholas Donoghoe , Perry C Siatis , Richard A Gonzalez , Robert A Michael , Roxanne S Austin , Scott T Reents and Timothy J Richmond . View institutional ownership trends .

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC. Read More

Followed 160 TimesTop Followed

NYSE:ABBV

AbbVie (ABBV) Stock Price, News & Analysis

→ How to profit from the new boom in gold (From Stansberry Research) (Ad)

Free ABBV Stock Alerts

$174.08

-0.71 (-0.41%)

(As of 02/9/2024 08:55 PM ET)

Compare

Today's Range: $173.05
▼
$175.40
50-Day Range: $144.14
▼
$175.02
52-Week Range: $130.96
▼
$175.91

Volume: 3.50 million shs
Average Volume: 5.52 million shs
Market Capitalization: $313.34 billion

P/E Ratio: 63.77
Dividend Yield: 3.56%
Price Target: $175.36

Get AbbVie alerts:

AbbVie MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 0.7% Upside
$175.36 Price Target
Short Interest: Healthy
0.77% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.34
Upright™ Environmental Score
News Sentiment: 0.80
Based on 60 Articles This Week
Insider Trading: Selling Shares
$450,545 Sold Last Quarter
Proj. Earnings Growth: 9.16%
From $11.14 to $12.16 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.86 out of 5 stars

Medical Sector

25th out of 922 stocks

Pharmaceutical Preparations Industry

8th out of 424 stocks

2.3

Analyst's Opinion

Consensus Rating
AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $175.36, AbbVie has a forecasted upside of 0.7% from its current price of $174.08.
Amount of Analyst Coverage
AbbVie has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.77% of the float of AbbVie has been sold short.
Short Interest Ratio / Days to Cover
AbbVie has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AbbVie has recently increased by 12.25%, indicating that investor sentiment is decreasing significantly.

4.2

Dividend Strength

Dividend Leadership
AbbVie is a leading dividend payer. It pays a dividend yield of 3.56%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
AbbVie has been increasing its dividend for 52 years.
Dividend Coverage
The dividend payout ratio of AbbVie is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, AbbVie will have a dividend payout ratio of 50.99% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AbbVie has received a 52.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Adalimumab", "Ibrutinib", and "Hepatitis medication" products. See details.
Environmental Sustainability
The Environmental Impact score for AbbVie is -2.34.

3.2

News and Social Media Coverage

News Sentiment
AbbVie has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 60 news articles for AbbVie this week, compared to 20 articles on an average week.
Search Interest
219 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 39% compared to the previous 30 days.
MarketBeat Follows
159 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 87% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,545.00 in company stock.
Percentage Held by Insiders
Only 0.26% of the stock of AbbVie is held by insiders.
Percentage Held by Institutions
67.86% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for AbbVie are expected to grow by 9.16% in the coming year, from $11.14 to $12.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AbbVie is 63.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of AbbVie is 63.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.59.
Price to Earnings Growth Ratio
AbbVie has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AbbVie has a P/B Ratio of 17.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

Get all the details here >>>

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABBV Stock News Headlines

February 2, 2024 | marketbeat.com

AbbVie turns a corner; patent cliff fears were overblown

AbbVie's patent cliff is already a thing of the past with Skyrizi and Rinvoq outperforming and other assets also strong. Dividends are safe, growth is back.

February 1, 2024 | marketbeat.com

5 best stocks to buy in a bear market

Want income-producing assets and stable stocks? Look for stocks with stable cash flow in rock-solid industries for the best stocks to buy in a bear market.

February 12, 2024 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

January 19, 2024 | marketbeat.com

20 best healthcare dividend stocks to invest in (ABBV)

Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.

January 18, 2024 | marketbeat.com

How to pick the best dividend stocks (ABBV)

A stock’s dividend yield is a key metric for investors, so what is a good dividend yield? We’ll explore the answer in this article.

February 11, 2024 | fool.com

These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy

February 9, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Doximity (DOCS) and AbbVie (ABBV)

February 8, 2024 | msn.com

Cramer's Lightning Round: AbbVie is 'a very good company'

February 12, 2024 | The Oxford Club (Ad)

Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move

He started from nothing and became a multimillionaire...He's now one of the most sought-after trading experts...Yet he operates 858 miles from Wall Street.And now, he's revealing his #1 favorite strategy that targets MASSIVE weekly profits with just one stock ticker.

February 8, 2024 | markets.businessinsider.com

AbbVie's Vyalev Now Available For Advanced Parkinson's Disease In Canada

February 8, 2024 | msn.com

ImmunoGen spikes as HSR waiting period for AbbVie deal expires

February 8, 2024 | finance.yahoo.com

AbbVie's VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

February 8, 2024 | americanbankingnews.com

Leerink Partnrs Comments on AbbVie Inc.'s Q1 2024 Earnings (NYSE:ABBV)

February 7, 2024 | benzinga.com

AbbVie Options Trading: A Deep Dive into Market Sentiment

February 7, 2024 | markets.businessinsider.com

AbbVie’s Hold Rating Maintained Amid Positive Growth Outlook and Pending Acquisition Outcomes

February 7, 2024 | seekingalpha.com

AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding

February 7, 2024 | americanbankingnews.com

Truist Financial Increases AbbVie (NYSE:ABBV) Price Target to $195.00

February 7, 2024 | americanbankingnews.com

FY2027 EPS Estimates for AbbVie Inc. (NYSE:ABBV) Lifted by Analyst

February 7, 2024 | americanbankingnews.com

AbbVie (NYSE:ABBV) PT Raised to $195.00

February 7, 2024 | americanbankingnews.com

AbbVie (NYSE:ABBV) PT Raised to $185.00

February 6, 2024 | markets.businessinsider.com

Calibr-Skaggs, AbbVie To Develop Novel Cell Therapies For Solid Tumors And Autoimmune Diseases

February 6, 2024 | seekingalpha.com

AbbVie: Game Changer

February 6, 2024 | tmcnet.com

Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

February 6, 2024 | seekingalpha.com

AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq

February 6, 2024 | realmoney.thestreet.com

AbbVie price target raised by $7 at UBS, here's why

February 6, 2024 | fool.com

2 Magnificent Dividend Growth Stocks to Load Up On Right Now

February 6, 2024 | americanbankingnews.com

AbbVie (NYSE:ABBV) Price Target Increased to $189.00 by Analysts at Raymond James

See More Headlines

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 11/15 Dividend: 10/12/2023
Dividend Payable: 11/15/2023
Ex-Dividend for 2/15 Dividend: 1/12/2024
Last Earnings: 2/02/2024
Today: 2/12/2024
Dividend Payable: 2/15/2024
Next Earnings (Estimated): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:ABBV
CUSIP: 00287Y10
CIK: 1551152
Web: www.abbvie.com
Phone: (847) 932-7900
Fax: 302-655-5049
Employees: 50,000
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $175.36
High Stock Price Target: $196.00
Low Stock Price Target: $150.00
Potential Upside/Downside: +0.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.73
Trailing P/E Ratio: 63.77
Forward P/E Ratio: 15.63
P/E Growth: 2.21
Net Income: $4.86 billion
Net Margins: 8.95%
Pretax Margin: 11.51%
Return on Equity: 154.73%
Return on Assets: 14.60%

Debt

Debt-to-Equity Ratio: 4.59
Current Ratio: 0.96
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: $54.32 billion
Price / Sales: 5.77
Cash Flow: $18.70 per share
Price / Cash Flow: 9.31
Book Value: $9.78 per share
Price / Book: 17.80

Miscellaneous

Outstanding Shares: 1,800,000,000
Free Float: 1,795,320,000
Market Cap: $313.34 billion
Optionable: Optionable
Beta: 0.57

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Richard A. Gonzalez (Age 70)
Chairman & CEO
Comp: $6.95M
Mr. Robert A. Michael (Age 54)
President & COO
Comp: $4M
Mr. Scott T. Reents (Age 56)
Executive VP & CFO
Comp: $2.97M
Dr. Azita Saleki-Gerhardt Ph.D. (Age 61)
Executive VP & COO
Comp: $2.58M
Mr. Jeffrey Ryan Stewart (Age 55)
Executive VP & Chief Commercial Officer
Comp: $2.98M
Dr. Thomas J. Hudson M.D. (Age 62)
Senior VP & Chief Scientific Officer of Global Research
Ms. Elizabeth Shea
Senior Vice President of Investor Relations
Mr. Sanjay Narayan
SVP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal
Ms. Tracie Haas
Senior Vice President of Corporate Responsibility, Brand & Communications
Mr. Timothy J. Richmond (Age 58)
Executive VP & Chief Human Resources Officer
Comp: $1.12M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABBV Stock Analysis - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.
What is AbbVie's stock price target for 2024?: 15 brokerages have issued 12-month price targets for AbbVie's shares. Their ABBV share price targets range from $150.00 to $196.00. On average, they anticipate the company's share price to reach $175.36 in the next year. This suggests a possible upside of 0.7% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.
How have ABBV shares performed in 2024?: AbbVie's stock was trading at $154.97 at the start of the year. Since then, ABBV stock has increased by 12.3% and is now trading at $174.08.
View the best growth stocks for 2024 here.
Are investors shorting AbbVie?: AbbVie saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 13,560,000 shares, an increase of 12.3% from the December 31st total of 12,080,000 shares. Based on an average trading volume of 5,580,000 shares, the days-to-cover ratio is currently 2.4 days. Approximately 0.8% of the shares of the company are short sold.
View AbbVie's Short Interest.
When is AbbVie's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our ABBV earnings forecast.
How were AbbVie's earnings last quarter?: AbbVie Inc. (NYSE:ABBV) released its earnings results on Friday, February, 2nd. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.76 by $0.03. The business had revenue of $14.30 billion for the quarter, compared to analysts' expectations of $14.02 billion. AbbVie had a trailing twelve-month return on equity of 154.73% and a net margin of 8.95%. The business's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $3.60 earnings per share.
Read the conference call transcript.
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?: AbbVie declared a quarterly dividend on Friday, October 27th. Investors of record on Tuesday, January 16th will be given a dividend of $1.55 per share on Thursday, February 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Friday, January 12th. This is a positive change from the stock's previous quarterly dividend of $1.48.
Read our dividend analysis for ABBV.
Is AbbVie a good dividend stock?: AbbVie (NYSE:ABBV) pays an annual dividend of $6.20 per share and currently has a dividend yield of 3.56%. The company has been increasing its dividend for 52 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 227.11%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 50.99% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What ETFs hold AbbVie's stock?: ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), iShares Core High Dividend ETF (HDV), Invesco Pharmaceuticals ETF (PJP), Simplify Health Care ETF (PINK), Health Care Select Sector SPDR Fund (XLV) and VanEck Pharmaceutical ETF (PPH).
What guidance has AbbVie issued on next quarter's earnings?: AbbVie issued an update on its first quarter 2024 earnings guidance on Friday, February, 2nd. The company provided earnings per share guidance of 2.300-2.340 for the period, compared to the consensus estimate of 2.310. The company issued revenue guidance of $11.9 billion-$11.9 billion, compared to the consensus revenue estimate of $11.4 billion.
What is Richard A. Gonzalez's approval rating as AbbVie's CEO?: 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.
What other stocks do shareholders of AbbVie own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).
Who are AbbVie's major shareholders?: AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (1.36%), Norges Bank (1.16%), Massachusetts Financial Services Co. MA (0.47%), Dimensional Fund Advisors LP (0.45%), Franklin Resources Inc. (0.42%) and California Public Employees Retirement System (0.34%). Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents and Timothy J Richmond.
View institutional ownership trends.
How do I buy shares of AbbVie?: Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does AbbVie have any subsidiaries?: The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More

This page (NYSE:ABBV) was last updated on 2/12/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

AbbVie MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AbbVie Stock (NYSE:ABBV)

ABBV Stock Price History

ABBV Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ABBV Stock Analysis - Frequently Asked Questions

Overall MarketRank^™